Duration of signs and survival in premenopausal women with breast cancer

被引:12
|
作者
Love, RR
Duc, NB
Baumann, LC
Anh, PTH
Van To, T
Qian, Z
Havighurst, TC
机构
[1] Univ Wisconsin, Sch Med, Dept Med, Sect Med Oncol, Madison, WI USA
[2] Natl Canc Inst, Hosp K, Hanoi, Vietnam
[3] Univ Wisconsin, Sch Nursing, Madison, WI USA
[4] Peoples Hosp Haimen City, Haimen City, Jiangsu, Peoples R China
[5] Univ Wisconsin, Sch Med, Dept Biostat & Med Informat, Madison, WI USA
关键词
breast cancer; delay; signs; survival;
D O I
10.1023/B:BREA.0000032980.55245.c3
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Condensed. Among 550 women reporting a lump as the first sign of breast cancer, those with this sign for 6 29 months compared to those with 1 - 6 months, had bigger tumors and more frequent axillary node involvement. Overall survival, however, was not significantly different in these two groups. Background. The relationship of delay in diagnosis of breast cancer to survival is uncertain. Methods. We evaluated the relationship of patient-reported duration of signs of breast cancer to survival in participants in a clinical trial of adjuvant hormonal therapy in Vietnam and China. Results. Among 550 women reporting a lump as the first sign of breast cancer and information on when this appeared, the median duration of this sign before diagnosis was 6 months. Comparing two groups of patients with durations of lumps 1 - 6 months and 6 - 29 months, the group with longer duration of lumps had larger tumors clinically and pathologically ( p = 0.0006, and p = 0.004), more frequent axillary node involvement ( p = 0.008), and shorter but not statistically different disease-free and overall survival from the time of diagnosis ( p = 0.09 and 0.35, respectively). Conclusions. Breast cancer evolves slowly in the detectable period of its natural history. The impact of delays in diagnosis of less than 6 months is likely to be very limited; delays more than 6 months appear to have some, but marginal impact on survival.
引用
收藏
页码:117 / 124
页数:8
相关论文
共 50 条
  • [21] BREAST-CANCER IN PREMENOPAUSAL AND POSTMENOPAUSAL WOMEN
    STAVRAKY, K
    EMMONS, S
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1974, 53 (03) : 647 - 654
  • [22] ANDROGENS AND BREAST-CANCER IN PREMENOPAUSAL WOMEN
    SECRETO, G
    TONIOLO, P
    PISANI, P
    RECCHIONE, C
    CAVALLERI, A
    FARISELLI, G
    TOTIS, A
    DIPIETRO, S
    BERRINO, F
    CANCER RESEARCH, 1989, 49 (02) : 471 - 476
  • [23] Breast Cancer Risks in Premenopausal Women: A Review
    Bumpers, Harvey L.
    CURRENT WOMENS HEALTH REVIEWS, 2005, 1 (03) : 261 - 271
  • [24] Ribociclib in premenopausal women with advanced breast cancer
    Foukakis, Theodoros
    LANCET ONCOLOGY, 2018, 19 (07): : 850 - 852
  • [25] Ovarian reserve in premenopausal women with breast cancer
    Zong, Xiangyun
    Yu, Yang
    Chen, Wenhu
    Zong, Weiwei
    Yang, Hongjian
    Chen, Xuan
    BREAST, 2022, 64 : 143 - 150
  • [26] Tamoxifen for treatment of premenopausal women with breast cancer
    Lam, RY
    Chlebowski, RT
    CANCER INVESTIGATION, 2000, 18 (07) : 681 - 684
  • [27] Individual breast cancer risk in premenopausal women
    de Souza, RM
    Lazzaron, AR
    Defferrari, R
    Borba, AA
    Scherer, L
    Frasson, AL
    EUROPEAN JOURNAL OF CANCER, 1998, 34 : S24 - S24
  • [28] ANDROGENS AND BREAST-CANCER IN PREMENOPAUSAL WOMEN
    TONIOLO, P
    SECRETO, G
    PISANI, P
    RECCHIONE, C
    CAVALLERI, A
    BERRINO, F
    BREAST CANCER RESEARCH AND TREATMENT, 1988, 12 (01) : 140 - 140
  • [29] Management of premenopausal women with primary breast cancer
    Woodman, CBJ
    Singleton, J
    Coyne, J
    Baildam, A
    BRITISH JOURNAL OF SURGERY, 1996, 83 (09) : 1256 - 1257
  • [30] Reproductive factors and premenopausal breast cancer survival.
    Enger, SM
    Bernstein, L
    AMERICAN JOURNAL OF EPIDEMIOLOGY, 2001, 153 (11) : S36 - S36